PRO-OCULAR™ – THE ONLY PRODUCT TO TREAT DED BY TARGETING THE OPHTHALMIC BRANCH OF THE TRIGEMINAL NERVE

Our Pro-ocular™ gel treats DED symptoms by engaging the central nervous system to produce the body’s own tear film.

Relieves ocular discomfort
Reduces blurry vision
Decreases ocular inflammation
Nourishes ocular tissue to promote healing

Convenient and Tolerable

Current eye drop and nasal treatments often fall short, leading to user dissatisfaction. Pro-ocular™ offers an easy to use solution with superior patient compliance and results.

Ease of Use

Pro-ocular™ can be applied anytime, anywhere, without the mess of and discomfort of eye drops.

Low Side Effects

Our patented transappendageal forehead delivery method eliminates the blurry vision, stinging, burning, and red eyes often associated with eye drop therapy and sneezing associated with nasal sprays

Neuro Signaling via the Ophthalmic Branch of the Trigeminal Nerve

Mechanism of Action

Pro-ocular’s mechanism of action involves targeting the underlying immunological processes that occur in DED and other autoimmune diseases, such as Sjögren syndrome and oGvHD. It is designed to modulate the immune response in the eye, which is a key factor in the development and progression of these diseases. By targeting specific pathways, Pro-ocular™ aims to reduce inflammation and damage to the ocular surface, ultimately improving patient outcomes.

Pro-ocular™ gel, when applied and massaged twice daily laterally to the forehead area, activates a neural pathway that leads to the stimulation of lacrimal and meibomian gland functions.

Subjects using Pro-ocular™ in placebo-controlled clinical trials experienced rapid and durable improvement in signs and symptoms of DED, and improved quality of life.

Join Our Mission

Signal12 is raising capital to complete Phase 3 trials and bring Pro-ocular to market. Invest in a future where dry eye sufferers can enjoy lasting relief and improved vision.

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a clinical-stage dry eye company that develops novel therapies to address ophthalmic diseases. Through three Phase 2 clinical studies, the company’s proprietary topical drug, Pro-ocular™ has demonstrated efficacy in safely and effectively reducing the signs and symptoms of dry eye disease (DED). Pro-ocular™ is the first product for DED to utilize transappendageal delivery, and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. The company has offices in Greenwich, CT and Boston, MA.

Signal12 is actively raising capital to complete Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected].